Guardant Health/$GH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Guardant Health
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Ticker
$GH
Sector
Primary listing
Employees
2,498
Headquarters
Website
Guardant Health Metrics
BasicAdvanced
$12bn
-
-$3.32
1.65
-
Price and volume
Market cap
$12bn
Beta
1.65
52-week high
$120.74
52-week low
$36.36
Average daily volume
2.1m
Financial strength
Current ratio
4.843
Quick ratio
4.425
Long term debt to equity
-1,694.204
Total debt to equity
-1,694.204
Interest coverage (TTM)
-111.96%
Profitability
EBITDA (TTM)
-394.548
Gross margin (TTM)
64.46%
Net profit margin (TTM)
-42.39%
Operating margin (TTM)
-44.22%
Effective tax rate (TTM)
0.30%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
-15.59%
Return on equity (TTM)
348.42%
Valuation
Price to revenue (TTM)
11.64
Price to book
-119.93
Price to tangible book (TTM)
-58.82
Price to free cash flow (TTM)
-49.043
Free cash flow yield (TTM)
-2.04%
Free cash flow per share (TTM)
-1.859
Growth
Revenue change (TTM)
32.88%
Earnings per share change (TTM)
-6.61%
3-year revenue growth (CAGR)
29.75%
3-year earnings per share growth (CAGR)
-19.67%
What the Analysts think about Guardant Health
Analyst ratings (Buy, Hold, Sell) for Guardant Health stock.
Guardant Health Financial Performance
Revenues and expenses
Guardant Health Earnings Performance
Company profitability
Guardant Health News
AllArticlesVideos
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
Business Wire·1 day ago
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
Business Wire·5 days ago
Why Is Guardant Health Stock Falling On Tuesday?
Benzinga·7 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Guardant Health stock?
Guardant Health (GH) has a market cap of $12B as of May 05, 2026.
What is the P/E ratio for Guardant Health stock?
The price to earnings (P/E) ratio for Guardant Health (GH) stock is 0 as of May 05, 2026.
Does Guardant Health stock pay dividends?
No, Guardant Health (GH) stock does not pay dividends to its shareholders as of May 05, 2026.
When is the next Guardant Health dividend payment date?
Guardant Health (GH) stock does not pay dividends to its shareholders.
What is the beta indicator for Guardant Health?
Guardant Health (GH) has a beta rating of 1.65. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.